Neuropharmacological insight into preventive intervention in posttraumatic epilepsy based on regulating glutamate homeostasis
© 2023 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd..
BACKGROUND: Posttraumatic epilepsy (PTE) is one of the most critical complications of traumatic brain injury (TBI), significantly increasing TBI patients' neuropsychiatric symptoms and mortality. The abnormal accumulation of glutamate caused by TBI and its secondary excitotoxicity are essential reasons for neural network reorganization and functional neural plasticity changes, contributing to the occurrence and development of PTE. Restoring glutamate balance in the early stage of TBI is expected to play a neuroprotective role and reduce the risk of PTE.
AIMS: To provide a neuropharmacological insight for drug development to prevent PTE based on regulating glutamate homeostasis.
METHODS: We discussed how TBI affects glutamate homeostasis and its relationship with PTE. Furthermore, we also summarized the research progress of molecular pathways for regulating glutamate homeostasis after TBI and pharmacological studies aim to prevent PTE by restoring glutamate balance.
RESULTS: TBI can lead to the accumulation of glutamate in the brain, which increases the risk of PTE. Targeting the molecular pathways affecting glutamate homeostasis helps restore normal glutamate levels and is neuroprotective.
DISCUSSION: Taking glutamate homeostasis regulation as a means for new drug development can avoid the side effects caused by direct inhibition of glutamate receptors, expecting to alleviate the diseases related to abnormal glutamate levels in the brain, such as PTE, Parkinson's disease, depression, and cognitive impairment.
CONCLUSION: It is a promising strategy to regulate glutamate homeostasis through pharmacological methods after TBI, thereby decreasing nerve injury and preventing PTE.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
CNS neuroscience & therapeutics - 29(2023), 9 vom: 01. Sept., Seite 2430-2444 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gao, Yuan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.08.2023 Date Revised 07.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cns.14294 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358109981 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358109981 | ||
| 003 | DE-627 | ||
| 005 | 20231226074039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cns.14294 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM358109981 | ||
| 035 | |a (NLM)37309302 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gao, Yuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neuropharmacological insight into preventive intervention in posttraumatic epilepsy based on regulating glutamate homeostasis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.08.2023 | ||
| 500 | |a Date Revised 07.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Posttraumatic epilepsy (PTE) is one of the most critical complications of traumatic brain injury (TBI), significantly increasing TBI patients' neuropsychiatric symptoms and mortality. The abnormal accumulation of glutamate caused by TBI and its secondary excitotoxicity are essential reasons for neural network reorganization and functional neural plasticity changes, contributing to the occurrence and development of PTE. Restoring glutamate balance in the early stage of TBI is expected to play a neuroprotective role and reduce the risk of PTE | ||
| 520 | |a AIMS: To provide a neuropharmacological insight for drug development to prevent PTE based on regulating glutamate homeostasis | ||
| 520 | |a METHODS: We discussed how TBI affects glutamate homeostasis and its relationship with PTE. Furthermore, we also summarized the research progress of molecular pathways for regulating glutamate homeostasis after TBI and pharmacological studies aim to prevent PTE by restoring glutamate balance | ||
| 520 | |a RESULTS: TBI can lead to the accumulation of glutamate in the brain, which increases the risk of PTE. Targeting the molecular pathways affecting glutamate homeostasis helps restore normal glutamate levels and is neuroprotective | ||
| 520 | |a DISCUSSION: Taking glutamate homeostasis regulation as a means for new drug development can avoid the side effects caused by direct inhibition of glutamate receptors, expecting to alleviate the diseases related to abnormal glutamate levels in the brain, such as PTE, Parkinson's disease, depression, and cognitive impairment | ||
| 520 | |a CONCLUSION: It is a promising strategy to regulate glutamate homeostasis through pharmacological methods after TBI, thereby decreasing nerve injury and preventing PTE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a excitatory neurotoxicity | |
| 650 | 4 | |a glutamate homeostasis | |
| 650 | 4 | |a neuropharmacological research | |
| 650 | 4 | |a posttraumatic epilepsy | |
| 650 | 4 | |a preventive treatment | |
| 650 | 4 | |a traumatic brain injury | |
| 650 | 7 | |a Glutamic Acid |2 NLM | |
| 650 | 7 | |a 3KX376GY7L |2 NLM | |
| 700 | 1 | |a Liu, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Niu, Jianguo |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Shengsong |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Xiaodong |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Jianqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Lin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS neuroscience & therapeutics |d 2008 |g 29(2023), 9 vom: 01. Sept., Seite 2430-2444 |w (DE-627)NLM17958930X |x 1755-5949 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:9 |g day:01 |g month:09 |g pages:2430-2444 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cns.14294 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 9 |b 01 |c 09 |h 2430-2444 | ||